Loading data for ARDX — first visit, this takes a few seconds.
Ardelyx, Inc. (ARDX)
NasdaqGM: ARDX
· 即時價格 · USD
3.78
+0.07 (1.89%)
收盤價： Sep 04, 2026, 8:00 PM
3.76
-0.53%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Ardelyx, Inc.（ARDX）股價、分析與資料
無可用資料
| 買價 | 3.62 |
| 市值 | 976M |
| 營收 (ttm) | 451M |
| 淨利（ttm） | -55.7M |
| 0.69 | |
| -0.23 | |
| n/a | |
| 15 | |
| P/B (ttm) | 6.32 |
| P/S (ttm) | 2.16 |
| 財報日期 | Oct 31, 2024 |
| 賣價 | 6.45 |
| 成交量 | 2,982,312 |
| 20 日平均成交量 | 4,225,625 |
| 開盤價 | 3.68 |
| 前收盤價 | 3.71 |
| 當日區間 | 3.68 - 3.78 |
| 52 週範圍 | 3.68 - 8.40 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nter...
完整的公司簡介財報驚奇
Ardelyx 已於 Aug 6, 2026 公布季度財報：
- 營收為 $120.88M 低於預期 $0, 年增 23.77% 成長.
- 每股盈餘為 -0.07 低於預期 -0.02, 年增 -450.00% 下滑.
第 1 頁，共 2 頁